The Experts below are selected from a list of 234 Experts worldwide ranked by ideXlab platform
Liisa A M Galea - One of the best experts on this subject based on the ideXlab platform.
-
Premarin has opposing effects on spatial learning neural activation and serum cytokine levels in middle aged female rats depending on reproductive history
Neurobiology of Aging, 2018Co-Authors: Liisa A M Galea, Meighen M Roes, Christina J Dimech, Cherylemiliane T Chow, Rand Mahmoud, Stephanie E Lieblich, Paula DuartegutermanAbstract:Abstract Menopause is associated with cognitive decline, and hormone therapies (HTs) may improve cognition depending on type and timing of HTs. Previous parity may influence cognition in later life. We investigated how primiparity and long-term ovariectomy influence cognition, neurogenesis, hormones, cytokines, and neuronal activation in middle-aged rats in response to Premarin, an HT. Nulliparous and primiparous rats were sham-ovariectomized or ovariectomized, administered vehicle or Premarin 6 months later, and all rats were trained in the Morris water maze. Premarin improved early spatial learning and memory in nulliparous rats but impaired early learning in primiparous rats. With training, primiparity increased hippocampal neurogenesis, and Premarin decreased immature neurons, regardless of parity. Moreover, Premarin increased serum tumor necrosis factor α and the CXC chemokine ligand 1 (CXCL1) in trained nulliparous, but not primiparous, rats. However, Premarin decreased the expression of the immediate early gene zif268 in the dorsal CA3 region in primiparous rats after training. Thus, primiparity alters how Premarin affects spatial learning, neuronal activation, and serum cytokines. These findings have implications for the treatment of age-associated cognitive decline in women.
-
Premarin has opposing effects on spatial learning neural activiation and serum cytokine levels in middle age dependent on reproductive history
bioRxiv, 2017Co-Authors: Liisa A M Galea, Meighen M Roes, Cherylemiliane T Chow, Rand Mahmoud, Stephanie E Lieblich, Van Den Brink C, Paula DuartegutermanAbstract:Menopause is associated with cognitive decline, and hormone therapies (HT) can improve cognition dependent on time since menopause. Previous parity also influences cognition in later life. The present study investigated how primiparity and long-term ovariectomy influence cognition, hippocampal neurogenesis, and neuronal activation in middle-aged rats in response to the HT, Premarin. Nulliparous and primiparous rats were sham-ovariectomized or ovariectomized, administered vehicle or Premarin six months later, and trained in the Morris water maze. Premarin improved spatial learning and memory in nulliparous rats, but impaired spatial and reversal learning in primiparous rats. Primiparity increased hippocampal neurogenesis, whereas Premarin treatment decreased immature neurons in both primiparous and nulliparous middle-aged rats in a region-specific manner. Moreover, Premarin increased serum TNFα and KC/GRO in nulliparous, but not primiparous, rats, whereas Premarin increased zif268 expression in the CA3 region of the hippocampus in primiparous rats. Thus, primiparity alters how Premarin affects spatial learning, neuronal activation, serum cytokines, and adrenal mass. These findings have implications for the tailored treatment of age-associated cognitive decline in women.
-
The hormone therapy, Premarin, impairs hippocampus-dependent spatial learning and memory and reduces activation of new granule neurons in response to memory in female rats.
Neurobiology of aging, 2012Co-Authors: Cindy K. Barha, Liisa A M GaleaAbstract:Estrogens have been implicated as possible therapeutic agents for improving cognition in postmenopausal women and have been linked to neurodegenerative disorders such as Alzheimer's disease. However, the utility of Premarin (Wyeth Pharmaceuticals, Markham, ON, Canada), a conjugated equine estrogen and the most commonly prescribed hormone therapy, has recently been questioned. The purpose of this study was to investigate the effects of Premarin at 2 different doses (10 or 20 μg) on hippocampus-dependent spatial learning and memory, hippocampal neurogenesis, and new neuronal activation using a rodent model of surgical menopause. Rats were treated daily with subcutaneous injections of Premarin and trained on the spatial working/reference memory version of the radial arm maze. Premarin impaired spatial reference and working learning and memory, increased hippocampal neurogenesis, but either decreased or increased activation of new neurons in response to memory retrieval as indexed by the expression of the immediate early gene product zif268, depending on the maturity of cells examined. This activation of new neurons was related to impaired performance in Premarin-treated but not control-treated female rats. These results indicate that Premarin may be impairing hippocampus-dependent learning and memory by negatively altering the neurogenic environment in the dentate gyrus thus disrupting normal activity of new neurons.
Guo Wen-jua - One of the best experts on this subject based on the ideXlab platform.
-
THE EXPLORATION OF THE THERAPY OF Premarin VAGINAL CREAM TO STRESS URINARY INCONTINENCE IN POST-MENOPAUSAL WOMEN.
Modern Preventive Medicine, 2005Co-Authors: Guo Wen-juaAbstract:Objective:To explore the nooperation treatment and improvement methods to stress urinary incontinence in post-menopausal women.Methods:Proceeding two methods of using Premarin vaginal cream complied by Kegel exercises and Premarin vaginal cream singly,the curative effects of the two methods were compared for urinary incontinence in post-menopausal women.Results:The symptom decreased by 20%,and there was no significant difference of the quantity of urinary incontinence after using Premarin vaginal cream singly(P0.05).The symptom decreased by 85% using Premarin vaginal cream complied by Kegel exercises,and there was significant difference of the quantity of urinary incontinence(P0.01).Conclusion:The outcome was obvious by using Premarin vaginal cream and Kegel exercises in post-menopausal women.It was a simple and safe therapy method,and could be applied in clinical practice.
Paula Duarteguterman - One of the best experts on this subject based on the ideXlab platform.
-
Premarin has opposing effects on spatial learning neural activation and serum cytokine levels in middle aged female rats depending on reproductive history
Neurobiology of Aging, 2018Co-Authors: Liisa A M Galea, Meighen M Roes, Christina J Dimech, Cherylemiliane T Chow, Rand Mahmoud, Stephanie E Lieblich, Paula DuartegutermanAbstract:Abstract Menopause is associated with cognitive decline, and hormone therapies (HTs) may improve cognition depending on type and timing of HTs. Previous parity may influence cognition in later life. We investigated how primiparity and long-term ovariectomy influence cognition, neurogenesis, hormones, cytokines, and neuronal activation in middle-aged rats in response to Premarin, an HT. Nulliparous and primiparous rats were sham-ovariectomized or ovariectomized, administered vehicle or Premarin 6 months later, and all rats were trained in the Morris water maze. Premarin improved early spatial learning and memory in nulliparous rats but impaired early learning in primiparous rats. With training, primiparity increased hippocampal neurogenesis, and Premarin decreased immature neurons, regardless of parity. Moreover, Premarin increased serum tumor necrosis factor α and the CXC chemokine ligand 1 (CXCL1) in trained nulliparous, but not primiparous, rats. However, Premarin decreased the expression of the immediate early gene zif268 in the dorsal CA3 region in primiparous rats after training. Thus, primiparity alters how Premarin affects spatial learning, neuronal activation, and serum cytokines. These findings have implications for the treatment of age-associated cognitive decline in women.
-
Premarin has opposing effects on spatial learning neural activiation and serum cytokine levels in middle age dependent on reproductive history
bioRxiv, 2017Co-Authors: Liisa A M Galea, Meighen M Roes, Cherylemiliane T Chow, Rand Mahmoud, Stephanie E Lieblich, Van Den Brink C, Paula DuartegutermanAbstract:Menopause is associated with cognitive decline, and hormone therapies (HT) can improve cognition dependent on time since menopause. Previous parity also influences cognition in later life. The present study investigated how primiparity and long-term ovariectomy influence cognition, hippocampal neurogenesis, and neuronal activation in middle-aged rats in response to the HT, Premarin. Nulliparous and primiparous rats were sham-ovariectomized or ovariectomized, administered vehicle or Premarin six months later, and trained in the Morris water maze. Premarin improved spatial learning and memory in nulliparous rats, but impaired spatial and reversal learning in primiparous rats. Primiparity increased hippocampal neurogenesis, whereas Premarin treatment decreased immature neurons in both primiparous and nulliparous middle-aged rats in a region-specific manner. Moreover, Premarin increased serum TNFα and KC/GRO in nulliparous, but not primiparous, rats, whereas Premarin increased zif268 expression in the CA3 region of the hippocampus in primiparous rats. Thus, primiparity alters how Premarin affects spatial learning, neuronal activation, serum cytokines, and adrenal mass. These findings have implications for the tailored treatment of age-associated cognitive decline in women.
M. P. Dain - One of the best experts on this subject based on the ideXlab platform.
-
A Double-Blind, Double-Dummy, Comparative Study of Menorest 50® versus Premarin® 0.625mg in the Treatment of Menopausal Symptoms and the Prevention of Bone Loss in Patients with Menopausal Symptoms
Clinical Drug Investigation, 1996Co-Authors: J. W. W. Studd, K. Mccarthy, D. Zamblera, M. P. Dain, L. LannAbstract:Thirty-two menopausal women entered the study (16 in each treatment group), of whom 24 completed the trial. The objectives were to investigate the long term efficacy and the local and systemic tolerance of Menorest 50® and Premarin® in the control of menopausal symptoms. After a 4-week treatment-free run-in period, patients were treated with continuous estrogen therapy (a twice-weekly application with Menorest 50® or a daily oral administration of Premarin® 0.625mg) for 1 year, plus a sequential progestin. The main efficacy criterion was the reduction in the mean number of hot flushes per day at 12 months. This study was considered to be a pilot study to collect data on changes in the bone mineral density of lumbar spine (L1-L4) assessments from baseline to weeks 30 and 56. Menorest 50® and Premarin® produced similar results in the relief of menopausal symptoms over the 1-year period of treatment. The mean number of hot flushes per day decreased from 6.9 at baseline to 0.5 at 12 weeks and 0.1 at 12 months in the Menorest 50® group, and from 7.0 to 0.3 and 0.0, respectively, in the Premarin group. The lumbar spine and hip densitometry results revealed that Menorest 50® prevented bone loss to the same extent as Premarin®. Tolerance was similar, with approximately the same number of patients with adverse events, severe adverse events and related-to-study-drug adverse events in both groups. Menorest 50® and Premarin® 0.625mg demonstrated similar results over the 1-year treatment period in reducing the mean number of hot flushes and the severity score of menopausal symptoms, including vasomotor, psychological and urogenital symptoms.
-
a double blind double dummy comparative study of menorest 50 versus Premarin 0 625mg in the treatment of menopausal symptoms and the prevention of bone loss in patients with menopausal symptoms
Clinical Drug Investigation, 1996Co-Authors: J. W. W. Studd, K. Mccarthy, D. Zamblera, M. P. Dain, Le L LannAbstract:Thirty-two menopausal women entered the study (16 in each treatment group), of whom 24 completed the trial. The objectives were to investigate the long term efficacy and the local and systemic tolerance of Menorest 50® and Premarin® in the control of menopausal symptoms. After a 4-week treatment-free run-in period, patients were treated with continuous estrogen therapy (a twice-weekly application with Menorest 50® or a daily oral administration of Premarin® 0.625mg) for 1 year, plus a sequential progestin. The main efficacy criterion was the reduction in the mean number of hot flushes per day at 12 months. This study was considered to be a pilot study to collect data on changes in the bone mineral density of lumbar spine (L1-L4) assessments from baseline to weeks 30 and 56. Menorest 50® and Premarin® produced similar results in the relief of menopausal symptoms over the 1-year period of treatment. The mean number of hot flushes per day decreased from 6.9 at baseline to 0.5 at 12 weeks and 0.1 at 12 months in the Menorest 50® group, and from 7.0 to 0.3 and 0.0, respectively, in the Premarin group. The lumbar spine and hip densitometry results revealed that Menorest 50® prevented bone loss to the same extent as Premarin®. Tolerance was similar, with approximately the same number of patients with adverse events, severe adverse events and related-to-study-drug adverse events in both groups. Menorest 50® and Premarin® 0.625mg demonstrated similar results over the 1-year treatment period in reducing the mean number of hot flushes and the severity score of menopausal symptoms, including vasomotor, psychological and urogenital symptoms.
-
Efficacy and safety of Menorest (50 mikrog/day) compared to Premarin 0.625 mg in the treatment of menopausal symptoms and the prevention of bone loss, in menopausal women. A single-center, comparative, randomized, double-blind, double-dummy study.
Scandinavian journal of rheumatology. Supplement, 1996Co-Authors: J. W. W. Studd, D. Zamblera, K. Maccarthy, M. P. DainAbstract:Thirty-two (32) menopausal women were entered into the study (16 in each treatment group), of whom 24 completed the study. The objectives were to compare the long-term efficacy and the local and systemic tolerance of Menorest and Premarin in the control of menopausal symptoms, and the prevention of bone loss. After a 4-week treatment-free run-in period, patients were treated with continuous estrogen therapy (a twice weekly application with Menorest 50 or a daily oral administration of Premarin 0.625 mg) for one year. Patients were also given 20 mg oral Dydrogesterone per day for the last 12 days of each 28 day cycle of treatment. The main efficacy criterion was the reduction in the mean number of hot flushes per day at 12 months compared to baseline. This study was also considered as a pilot study to collect data on changes in the bone mineral density of the lumbar spine (L1-L4) assessments from baseline to week 30 and week 56.Menorest and Premarin were equally effective in the relief of menopausal sympto...
-
efficacy and safety of menorest 50 mikrog day compared to Premarin 0 625 mg in the treatment of menopausal symptoms and the prevention of bone loss in menopausal women a single center comparative randomized double blind double dummy study
Scandinavian journal of rheumatology. Supplement, 1996Co-Authors: J. W. W. Studd, D. Zamblera, K. Maccarthy, M. P. DainAbstract:Thirty-two (32) menopausal women were entered into the study (16 in each treatment group), of whom 24 completed the study. The objectives were to compare the long-term efficacy and the local and systemic tolerance of Menorest and Premarin in the control of menopausal symptoms, and the prevention of bone loss. After a 4-week treatment-free run-in period, patients were treated with continuous estrogen therapy (a twice weekly application with Menorest 50 or a daily oral administration of Premarin 0.625 mg) for one year. Patients were also given 20 mg oral Dydrogesterone per day for the last 12 days of each 28 day cycle of treatment. The main efficacy criterion was the reduction in the mean number of hot flushes per day at 12 months compared to baseline. This study was also considered as a pilot study to collect data on changes in the bone mineral density of the lumbar spine (L1-L4) assessments from baseline to week 30 and week 56.Menorest and Premarin were equally effective in the relief of menopausal sympto...
Douglas S Hepburn - One of the best experts on this subject based on the ideXlab platform.
-
17β estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis
Menopause, 2000Co-Authors: Jacques E Rioux, Corinne M Devlin, Morrie M Gelfand, Wilfred Steinberg, Douglas S HepburnAbstract:AbstractObjectives:The efficacy and safety of 25-μg 17β-estradiol vaginal tablets (Vagifem) were assessed and compared with 1.25-mg conjugated equine estrogen vaginal cream (Premarin Vaginal Cream) for the relief of menopausal-derived atrophic vaginitis, resulting from estrogen deficiency.Design:In